Question special

Dr. Davies and Dr. Montgomery mentioned earlier that the combination of PARPi with platinum is an attractive idea. Combining platinum chemotherapy with PARP inhibitors offers promise, since the inhibitors would lead to even more DNA damage in the tumor tissue with DNA repair mutations. And as Dr. Montgomery alluded to, the mechanisms of sensitivity of the two classes of agents aren't entirely overlapping.

At this juncture, I am curious what are the authors' thoughts about and/or experiences with combining PARP inhibition with platinum chemotherapy or perhaps simultaneous radiotherapy in order to exploit the potential synergy between PARP inhibition and other DNA-damaging agents?